Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature
- PMID: 27785429
- PMCID: PMC5071205
- DOI: 10.21037/tau.2016.09.07
Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature
Abstract
In the context of customized patient care for upper tract urothelial carcinoma (UTUC), decision-making could be facilitated by risk assessment and prediction tools. The aim of this study was to provide a critical overview of existing predictive models and to review emerging promising prognostic factors for UTUC. A literature search of articles published in English from January 2000 to June 2016 was performed using PubMed. Studies on risk group stratification models and predictive tools in UTUC were selected, together with studies on predictive factors and biomarkers associated with advanced-stage UTUC and oncological outcomes after surgery. Various predictive tools have been described for advanced-stage UTUC assessment, disease recurrence and cancer-specific survival (CSS). Most of these models are based on well-established prognostic factors such as tumor stage, grade and lymph node (LN) metastasis, but some also integrate newly described prognostic factors and biomarkers. These new prediction tools seem to reach a high level of accuracy, but they lack external validation and decision-making analysis. The combinations of patient-, pathology- and surgery-related factors together with novel biomarkers have led to promising predictive tools for oncological outcomes in UTUC. However, external validation of these predictive models is a prerequisite before their introduction into daily practice. New models predicting response to therapy are urgently needed to allow accurate and safe individualized management in this heterogeneous disease.
Keywords: Upper tract urothelial carcinoma (UTUC); biomarkers; disease recurrence; nomograms; predictive tools; prognosis; prognostic factors; risk stratification; survival.
Conflict of interest statement
Shahrokh F. Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06; methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19; prognostic methods for patients with prostatic disease. Granted 2004-08-05; soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He is advisory board member of Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, Wolff. He is speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi, Wolff. Romain Mathieu is consultant for Astellas, Ipsen, Janssen; and he is speaker of Janssen, Sanofi, Novartis, Takeda. The other authors have no conflicts of interest to declare.
Similar articles
-
Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification.Minerva Urol Nefrol. 2016 Aug;68(4):381-95. Epub 2016 Apr 28. Minerva Urol Nefrol. 2016. PMID: 27124417 Review.
-
Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.Eur Urol. 2012 Jul;62(1):100-14. doi: 10.1016/j.eururo.2012.02.030. Epub 2012 Feb 23. Eur Urol. 2012. PMID: 22381168 Review.
-
Upper urinary tract disease: what we know today and unmet needs.Transl Androl Urol. 2015 Jun;4(3):261-72. doi: 10.3978/j.issn.2223-4683.2015.05.01. Transl Androl Urol. 2015. PMID: 26816829 Free PMC article. Review.
-
Why are upper tract urothelial carcinoma two different diseases?Transl Androl Urol. 2016 Oct;5(5):636-647. doi: 10.21037/tau.2016.03.23. Transl Androl Urol. 2016. PMID: 27785420 Free PMC article. Review.
-
Risk stratification for upper tract urinary carcinoma.Transl Androl Urol. 2020 Aug;9(4):1799-1808. doi: 10.21037/tau.2019.12.21. Transl Androl Urol. 2020. PMID: 32944543 Free PMC article. Review.
Cited by
-
Preoperative hydronephrosis predicts adverse pathological features and postoperative survival in patients with high-grade upper tract urothelial carcinoma.Int Braz J Urol. 2021 Jan-Feb;47(1):159-168. doi: 10.1590/S1677-5538.IBJU.2020.0021. Int Braz J Urol. 2021. PMID: 33047921 Free PMC article.
-
Nomogram construction for predicting survival of patients with non-small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 patients.Oncol Lett. 2020 Jan;19(1):449-459. doi: 10.3892/ol.2019.11112. Epub 2019 Nov 19. Oncol Lett. 2020. PMID: 31897158 Free PMC article.
-
A novel LASSO-derived prognostic model predicting survival for non-small cell lung cancer patients with M1a diseases.Cancer Med. 2022 Mar;11(6):1561-1572. doi: 10.1002/cam4.4560. Epub 2022 Feb 6. Cancer Med. 2022. PMID: 35128839 Free PMC article.
-
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231159753. doi: 10.1177/15330338231159753. Technol Cancer Res Treat. 2023. PMID: 36855829 Free PMC article. Review.
-
Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy.Transl Androl Urol. 2017 Oct;6(5):987-990. doi: 10.21037/tau.2017.08.04. Transl Androl Urol. 2017. PMID: 29184801 Free PMC article. No abstract available.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources